Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifabutin versus rifampicin for staphylococcal prosthetic joint infection treated with DAIR
2020-000471-20Phase 3Active
- Sponsor
- Centre Hospitalier de Tourcoing
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Staphylococcal periprosthetic joint infection (SPJI) comparing Rifabutin arm with Rifampicin arm (2 arms). Primary endpoint: Treatment failure after one year of follow-up. Started Sep 2020; status: active.
02
Drugs
rifabutinrifampicin
03
Conditions
Staphylococcal periprosthetic joint infection (SPJI)
Beyond the preview
Go deeper on 2020-000471-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000471-20.